A phase IIb trial to assess the efficacy and tolerability of IPX 159 in patients with restless legs syndrome

Trial Profile

A phase IIb trial to assess the efficacy and tolerability of IPX 159 in patients with restless legs syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs IPX 159 (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors IMPAX Laboratories
  • Most Recent Events

    • 21 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Feb 2012 Planned number of patients changed from 120 to 160 as reported by ClinicalTrials.gov.
    • 02 Feb 2012 Planned end date (Feb 2013) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top